



Council of the
European Union

Brussels, 22 February 2024
(OR. en)

6550/24

INTER-REP 17	COMPET 218
GLOBAL GATEWAY 8	ECOFIN 236
COASI 27	FIN 186
COEST 133	CCG 7
COAFR 80	TRANS 113
MED 10	ENER 92
MAMA 52	ENV 212
COLAC 28	DEVGEN 25
COWEB 18	DIGIT 60

INFORMATION NOTE

From:	General Secretariat of the Council
To:	Permanent Representatives Committee/Council
Subject:	Univercells & MAV+ Presentation

Delegations will find in the annex a presentation given by an external stakeholder, on behalf of Univercells at the meeting of RELEX Counsellors – Horizontal Questions on February 23 2024. This presentation and the views expressed therein are solely those of the third party it originates from. This document cannot be regarded as stating an official position of the Council. It does not reflect the views of the Council or of its members.



Univercells & MAV+

Kate Antrobus – Chief Business Officer

Non-Confidential

Brussels, February 23

Disclaimer

This report has been produced by Univercells in February 2024. Neither the whole nor any part of this report may be distributed, reproduced, disclosed to, used or relied upon by any other person or used for any other purpose without the prior written consent of Univercells.

While the information provided herein is believed to be accurate, Univercells makes no representation or warranty, express or implied, as to the accuracy or completeness of such information. The information contained herein was prepared expressly for use herein and is based on certain assumptions and information available at the time this report was prepared. There is no representation, warranty or other assurance that any of the projections or estimates will be realized, and nothing contained within this report is or should be relied upon as a promise or representation as to the future. In furnishing this report Univercells reserves the right to amend or replace the report at any time and undertakes no obligation to provide the Users with access to any additional information.



Proprietary & Confidential @ Univercells 2024 | 2

Who we are
TODAY ...



Univercells is a biotech innovator.

Technology

CDMO

Advisory

Univercells designs processes and technology across drug design, development and delivery.

+400
People

With 41 nationalities



BILL & MELINDA
GATES foundation




World Health
Organization



Proprietary & Confidential @ Univercells 2024 | 4

Belgian company with Global Ambition




Our experiences in **AFRICA**





Afrigen
Biologics & Vaccines
An Avacare Health & IDC Company

VACCINES



Proprietary & Confidential @ Univercells 2024 | 7



Afrigen

Biologics & Vaccines
An Avacare Health & IDC Company

Support from key European stakeholders has helped this relationship at multiple levels.



300
Million
doses per year



BILL & MELINDA
GATES foundation

- › **Facility:** MADIBA. Multi-platform modular, adaptable facility.
- › **Products:** Measles-Rubella (viral vaccine); Rift Valley Fever (mRNA); and many others!
- › **Our support:** Supply of technology, CDMO manufacturing for clinical trial materials, project management, facility design, supply chain and workforce support, securing financing & funding, proposal writing...

Proprietary & Confidential @ Univercells 2024 | 9



mRNA enables us
to move into
locally-driven R&D



What did we
LEARN?



Key Learnings from our African Partnerships

Huge support

Continued momentum around African Vaccine Manufacturing from private and public sector, from local, international and supra-sovereign players.


Exporting Ecosystems

We don't need manufacturing facilities, we need sustainable, growing, innovative ecosystems.

Start with what you have

And there is a lot! So many compelling launchpads and entry point(s) to galvanize local manufacturing.


Continued momentum around African vaccine manufacturing



Exporting Ecosystems from Europe to Africa

- › Partnership of equals
- › Build the ecosystem
- › Close collaboration with local and international public stakeholders
- › Sustainable business model
- › Competitive value proposition

... And from LatAm and Asia!



Start with what you have, and build from there!

- › Thriving hospital networks;
- › Petrochemical industry;
- › Agricultural research institutes;
- › Clinical trial capacity;
- › Impressive Universities;
- › Medical Device Industry;
- › Pharmaceutical Distributors;

And local entrepreneurs!



FRANCE
BELGIUM

Proprietary & Confidential @ Univercells 2024 | 15

Insights for MAV+



Insights on our participation in MAV+



- › Powerful donor alignment and support
- › Political will and partnership facilitation
- › Technical support for regulatory authorities

But...

- › Hard for an SME to participate
- › EC & partners are difficult to navigate
- › What mechanisms of support are applicable today? Which ones are coming up?

Proprietary & Confidential @ Univercells 2024 | 17

Biologics available
to all !



Proprietary & Confidential @ Univercells 2024 | 18